Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Therapies targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-L1) (abbreviated as PD-(L)1) axis are a significant advancement in the treatment of many tumor types.However, many patients receiving these agents fail to respond or have an initial response followed by cancer progression.For these patients, while subsequent immun